Influence of sex on propofol metabolism, a pilot study: Implications for propofol anesthesia

European Journal of Clinical Pharmacology

Volumn 68, Issue 4, 2012, Pages 397-406

  Loryan, Irena ^a   Lindqvist, Marja ^a   Johansson, Inger ^a   Hiratsuka, Masahiro ^a,c   Van Der Heiden, Ilse ^b   Van Schaik, Ron Hn ^b   Jakobsson, Jan ^a   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

Anesthesia; CYP2B6; Metabolism; Propofol; Sex; UGT1A9

Indexed keywords

ALFENTANIL; CYTOCHROME P450; CYTOCHROME P450 2B6; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE 1A9; LIDOCAINE; PROPOFOL; URIDINE DIPHOSPHATE;

ADOLESCENT; ADULT; AGED; ANESTHESIA INDUCTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG TRANSFORMATION; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYDROXYLATION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SEX DIFFERENCE; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ANESTHETICS, INTRAVENOUS; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPOFOL; SEX FACTORS; YOUNG ADULT;

EID: 84860268964     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1132-2     Document Type: Article

References (40)

1. Glen JB, Hunter SC (1984) Pharmacology of an emulsion formulation of ICI 35 868. Br J Anaesth 56(6):617-626 (Pubitemid 14083289)
2. Iohom G, Ni Chonghaile M, O'Brien JK, Cunningham AJ, Fitzgerald DF, Shields DC (2007) An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia. Eur J Anaesthesiol 24(11):912-919 (Pubitemid 47548626)
3. Hoymork SC, Raeder J (2005) Why do women wake up faster than men from propofol anaesthesiač Br J Anaesth 95(5):627-633 (Pubitemid 41600024)
4. Simons PJ, Cockshott ID, Douglas EJ, Gordon EA, Hopkins K, Rowland M (1988) Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14 C-propofol. Xenobiotica 18(4):429-440
5. Sneyd JR, Simons PJ, Wright B (1994) Use of proton nmr spectroscopy to measure propofol metabolites in the urine of the female Caucasian patient. Xenobiotica 24(10):1021-1028 (Pubitemid 24357411)
6. Favetta P, Degoute CS, Perdrix JP, Dufresne C, Boulieu R, Guitton J (2002) Propofol metabolites in man following propofol induction and maintenance. Br J Anaesth 88(5):653-658 (Pubitemid 34498593)
7. Court MH, Duan SX, Hesse LM, Venkatakrishnan K, Greenblatt DJ (2001) Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 94(1):110-119 (Pubitemid 32055186)
8. Oda Y, Hamaoka N, Hiroi T, Imaoka S, Hase I, Tanaka K, Funae Y, Ishizaki T, Asada A (2001) Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 51(3):281-285 (Pubitemid 32391505)
9. Al Koudsi N, Tyndale RF (2010) Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. Xenobiotica 40(6):381-392. doi:10.3109/00498251003713958
10. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M (2007) Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8(7):743-759 (Pubitemid 47288975)
11. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Murdter TE, Roots I, Brockmoller J (2003) Bupropion and 4-OHbupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13(10):619-626 (Pubitemid 37311148)
12. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, Schuetz EG (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307(3):906-922 (Pubitemid 37494207)
13. Court MH (2005) Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400:104-116 (Pubitemid 43052418)
14. Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, Greenblatt DJ, von Moltke LL, Perussed L, Guillemette C (2004) Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence thatUGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14 (8):501-515 (Pubitemid 39100002)
15. Ramirez J, Liu W, Mirkov S, Desai AA, Chen P, Das S, Innocenti F, Ratain MJ (2007) Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. Drug Metab Dispos 35(12):2149-2153 (Pubitemid 350146199)
16. Haensch K, Schultz A, Krauss T, Grouven U, Schultz B (2009) Women need more propofol than men during EEG-monitored total intravenous anaesthesia / Frauen benotigen mehr Propofol als Manner wahrend EEG-uberwachter total-intravenoser Anasthesie. Biomed Tech (Berl) 54(2):76-82
17. Glass PS, Bloom M, Kearse L, Rosow C, Sebel P, Manberg P (1997) Bispectral analysis measures sedation and memory effects of propofol, midazolam, isoflurane, and alfentanil in healthy volunteers. Anesthesiology 86(4):836-847 (Pubitemid 27174724)
18. Gan TJ, Glass PS, Sigl J, Sebel P, Payne F, Rosow C, Embree P (1999) Women emerge from general anesthesia with propofol/ alfentanil/nitrous oxide faster than men. Anesthesiology 90 (5):1283-1287 (Pubitemid 29205630)
19. Schnider TW, Minto CF, Gambus PL, Andresen C, Goodale DB, Shafer SL, Youngs EJ (1998) The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology 88(5):1170-1182 (Pubitemid 28216859)
20. White M, Kenny GN, Schraag S (2008) Use of target controlled infusion to derive age and gender covariates for propofol clearance. Clin Pharmacokinet 47(2):119-127
21. Masui K, Upton RN, Doufas AG, Coetzee JF, Kazama T, Mortier EP, Struys MM (2010) The performance of compartmental and physiologically based recirculatory pharmacokinetic models for propofol: a comparison using bolus, continuous, and targetcontrolled infusion data. Anesth Analg 111(2):368-379
22. Glen JB, Servin F (2009) Evaluation of the predictive performance of four pharmacokineticmodels for propofol. Br J Anaesth 102(5):626-632
23. Vuyk J, Oostwouder CJ, Vletter AA, Burm AG, Bovill JG (2001) Gender differences in the pharmacokinetics of propofol in elderly patients during and after continuous infusion. Br J Anaesth 86 (2):183-188 (Pubitemid 32103405)
24. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31(6):755-761 (Pubitemid 36617664)
25. Ghotbi R, Gomez A, Milani L, Tybring G, Syvanen AC, Bertilsson L, Ingelman-Sundberg M, Aklillu E (2009) Allelespecific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J 9 (3):208-217
26. Court MH, Hay-Kraus BL, Hill DW, Kind AJ, Greenblatt DJ (1999) Propofol hydroxylation by dog liver microsomes: assay development and dog breed differences. Drug Metab Dispos 27 (11):1293-1299
27. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11 (5):399-415 (Pubitemid 32656581)
28. van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Schmidt J, Budde K, Kuypers D, Le Meur Y, van der Werf M, Mamelok R, van Gelder T (2009) UGT1A9-275 T>A/-2152 C> T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther 86(3):319-327
29. Vree TB, Lagerwerf AJ, Bleeker CP, de Grood PM (1999) Direct high-performance liquid chromatography determination of propofol and its metabolite quinol with their glucuronide conjugates and preliminary pharmacokinetics in plasma and urine of man. J Chromatogr B Biomed Sci Appl 721(2):217-228 (Pubitemid 29142344)
30. Guitton J, Buronfosse T, Desage M, Flinois JP, Perdrix JP, Brazier JL, Beaune P (1998) Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth 80(6):788-795 (Pubitemid 28282553)
31. Apfelbaum JL, Grasela TH, Hug CC Jr, McLeskey CH, Nahrwold ML, Roizen MF, Stanley TH, Thisted RA, Walawander CA, White PF (1993) The initial clinical experience of 1819 physicians in maintaining anesthesia with propofol: characteristics associated with prolonged time to awakening. Anesth Analg 77(4 Suppl): S10-S14 (Pubitemid 23286441)
32. Zhu T, Pang Q, McCluskey SA, Luo C (2008) Effect of propofol on hepatic blood flow and oxygen balance in rabbits. Can J Anaesth 55(6):364-370 (Pubitemid 351914321)
33. Richards MJ, Skues MA, Jarvis AP, Prys-Roberts C (1990) Total i.v. anaesthesia with propofol and alfentanil: dose requirements for propofol and the effect of premedication with clonidine. Br J Anaesth 65(2):157-163 (Pubitemid 20244560)
34. Hernandez JP, Mota LC, Huang W, Moore DD, Baldwin WS (2009) Sexually dimorphic regulation and induction of P450s by the constitutive androstane receptor (CAR). Toxicology 256(1- 2):53-64
35. Buckley DB, Klaassen CD (2009) Mechanism of genderdivergent UDP-glucuronosyltransferase mRNA expression in mouse liver and kidney. Drug Metab Dispos 37(4):834-840
36. Scandlyn MJ, Stuart EC, Rosengren RJ (2008) Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol 4(4):413-424 (Pubitemid 351728515)
37. Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, Gaedigk A, Suver C, Zhong H, Leeder JS, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich RG, Slatter JG, Schadt EE, Kasarskis A, Lum PY Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res 20 (8):1020-1036
38. Liu HF, Vincent-Viry M, Galteau MM, Gueguen R, Magdalou J, Nicolas A, Leroy P, Siest G (1991) Urinary glucuronide excretion of fenofibric and clofibric acid glucuronides in man. Is it polymorphicč Eur J Clin Pharmacol 41(2):153-159
39. Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al- Rohaimi A, von Moltke LL, Greenblatt DJ (2004) UDPglucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther 310(2):656-665 (Pubitemid 38988911)
40. Miners JO, Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51(3):347-369